Enterprise Value to EBITDA Ratio: Ascentage Pharma Group (AAPG)
International leukemia drug trials support the operating cash flow, which determines the current trajectory for Ascentage Pharma Group (AAPG). The EV/EBITDA metric, including depreciation and debt, demonstrates the market valuation of the business relative to its earnings, where 0.00 captures the current state of the parameter. Yan Daping is integrating global expertise into oncotherapy, although high R&D expenditures and geopolitics create financial challenges.
Metric breakdowns and analytics for ascentage.com (AAPG)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Ascentage Pharma Group|AAPG - Long-Term Debt to Capital|Short-Term Debt to Equity Ascentage Pharma|AAPG - Company Total Debt Obligations|Debts to Book Capitalization Ascentage Pharma Corp|AAPG - Company Long-Term Liabilities|Company Short-Term Debts Ascentage Pharma|Quick Liquidity ascentage.com
- business earnings and investment ratios data:
AAPG - Company Profit|Future Profit Ascentage Pharma Group|AAPG - Market Price to Net Income Ratio|Forward P/E Multiple Ascentage Pharma Group|AAPG - PEG Multiple|EV/EBITDA Multiple Ascentage Pharma Corp|AAPG - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Ascentage Pharma|AAPG - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ascentage.com|AAPG - Earnings per share increase in current year|Net earnings per share growth forecast for next year Ascentage Pharma Group
Comprehensive company analysis:Ascentage AAPG
Investors must filter out debt risks for Ascentage Pharma Group (AAPG), given the strict medical regulations for oncology drug development and the specifics of biomaterial disposal. An analysis of the EV/EBITDA ratio for this capital-intensive business allows for an assessment of the total enterprise value relative to operating profit before interest, taxes, depreciation, and amortization, where a decrease in this metric confirms the stability of the fundamental valuation and the reliability of the company's business model.
Competitors of Ascentage Pharma Group (AAPG)
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|CGON - EV/EBITDA Multiple|UroGen Pharma (URGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Bicara Therapeutics Inc - Business Value to Operating Income Before Depreciation|PSNL (Personalis Corp) - EV/EBITDA Multiple|Company Value to EBITDA Erasca Oncology ERAS|EV/EBITDA Multiple DCTH|EV/EBITDA Multiple ymabs.com (YMAB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aura Biosciences AURA|Total Company Value to Operating Income Before Depreciation Ratio Candel Therapeutics Inc. (CADL)|Accuray Inc. - EV/EBITDA Multiple|SELLAS Life Sciences (SLS) - Enterprise Value to EBITDA Ratio|ACTU: EV/EBITDA Multiple|Company Value to EBITDA citiusonc.com (CTOR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences Inc.|Enterprise Value to Operating Income Before Depreciation TARA (Protara Therapeutics Inc)|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Operating Income Before Depreciation Ratio WHWK|EV/EBITDA Multiple TCRX (TScan Therapeutics, Inc.)|EV/EBITDA Multiple Champions Oncology Inc CSBR|XBiotech USA - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple CEL-SCI Corporation (CVM)|OSTX: EV/EBITDA Multiple|Company Value to EBITDA Radiopharm Theranostics Ltd (RADX)|Enterprise Value to EBITDA Ratio ARTV|ANL: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple XLO (Xilio Therapeutics)|Business Value to Operating Income Before Depreciation RENB|Mural Bio - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|onkuretherapeutics.com (OKUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CytoMed Therapeutics Limited - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis Inc.|Enterprise Value to EBITDA Ratio Apollomics Corp (APLM)|EV/EBITDA Multiple THAR|EV/EBITDA Multiple advanbiomed.com (ADVB)|Genprex - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CLDI|Sunshine Biopharma - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Xenetic Biosciences (XBIO)|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|purple-biotech.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|Company Value to EBITDA BeiGene Ltd. BGNE|Enterprise Value to EBITDA Ratio CKPT (Checkpoint Therapeutics, Inc)|EV/EBITDA Multiple Elevation Oncology Inc. (ELEV)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA (Ikena Oncology Inc.) - Company Value to Operating Income Before Depreciation Ratio|Notable Labs - EV/EBITDA Multiple|VIRX - EV/EBITDA Multiple|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
